Transformative Breast Cancer Consortium
The Immune Solution to End Breast Cancer
The Transformative Breast Cancer Consortium (TBCC) consists of an integrated team of investigators. Our project groups were selected due to their extensive scientific interest and expertise, communication and collaborative research skills, and a shared perspective of their research goals
Upcoming Events and Deadlines
​​November 2023 (no monthly TBCC meeting due to holiday)
-
11/13: ZOOM Meeting: Salon Hours (2 pm EST)​​​​
December 2023 (no monthly TBCC meeting due to holiday)
-
12/11: ZOOM Meeting: Salon Hours (2 pm EST)​​
-
12/18: ANNUAL DOD IPR Meeting (Virtual)​​
January 2024
-
1/8: ZOOM Meeting: Salon Hours (2 pm EST)
-
1/25: ZOOM Meeting: TBCC BiAnnual Workshop (3 pm EST)
Project 1
Profiling the human breast tumor ecosystem to identify regulators of anti-tumor immunity
Patient Advocate Michele Atlan
Project 2
Dissecting the mechanisms of immune evasion employed by cancer drivers in breast cancer
Patient Advocate Michele Rakoff
Project 3
Targeting the epigenome as a therapeutic strategy for breast cancer
Patient Advocate Vernal Branch
Project 4
Study of the mammary myeloid regulation of T cells as a critical innate-adaptive immune checkpoint axis in the progression of BC
Patient Advocate Patty Spears
Project 5
A live biobank at inflexion points of triple negative breast cancer: the DIGNITY study
Patient Advocate Helen Schiff
TBCC Funded
Seed Projects
Generation of a novel octo-genic immune tolerant mouse (Octo-NG) to better model syngeneic tumor studies in fully immune-competent mice for TBCC groups
Zachary Hartman, PhD and Timothy Trotter, PhD
Duke University
Discovery of a dual combination WNT and PD-1/PD-L1 blockade therapy for treatment resistant and metastatic HER2+ breast cancers.
Joshua C. Snyder, Ph.D., Chaitanya R. Acharya, Ph.D., Joshua D. Ginzel, & Alexander Borowsky, M.D.
Duke University and UC Davis
Creating a 3D TNBC model of PTEN deficiency to discover immunoregulatory tumor epitopes
Wen Shen, PhD
Weill Cornell Medical College
Investigation of IGHG4/IgG4 expression in Breast Cancer
Co-Teams: Simon Knott, PhD and Zachary Hartman, PhD
Cedars-Sinai and Duke University